A randomized, double-blind, placebo-controlled, parallel group, phase 4, multi-center study of Vesicare (solifenacin succinate) in overactive bladder (OAB) subjects to evaluate symptom bother and health related quality of life VIBRANT: VESIcare Investigation of Bother And Quality of Life in Subjects with OAB

Trial Profile

A randomized, double-blind, placebo-controlled, parallel group, phase 4, multi-center study of Vesicare (solifenacin succinate) in overactive bladder (OAB) subjects to evaluate symptom bother and health related quality of life VIBRANT: VESIcare Investigation of Bother And Quality of Life in Subjects with OAB

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2010

At a glance

  • Drugs Solifenacin (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms VIBRANT
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 01 Jan 2010 Secondary endpoint 'Quality of life instrument' (change in HRQL total and domain scores on the OAB-q) has been met.
    • 16 May 2009 Results have been presented at the 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 06 May 2009 Primary endpoint 'Overactive Bladder Questionnaire' (change from baseline in OAB-q symptom bother scale score at 12 weeks) has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top